Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study

Journal of Clinical Oncology

Volumn 23, Issue 24, 2005, Pages 5795-5804

  Van Glabbeke, Martine ^a   Verweij, Jaap ^b   Casali, Paolo G ^b   Le Cesne, Axel ^b   Hohenberger, Peter ^b   Ray Coquard, Isabelle ^b   Schlemmer, Marcus ^b   Van Oosterom, Allan T ^b   Goldstein, David ^b   Sciot, Raf ^b   Hogendoorn, Pancras C W ^b   Brown, Michelle ^b   Bertulli, Rossella ^b   Judson, Ian R ^b  

^a EORTC DATA CENTER   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; CANCER LOCALIZATION; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ORGANIZATION; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LEUKOCYTE COUNT; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TUMOR VOLUME; VOMITING; DISEASE COURSE; DRUG RESISTANCE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 24944529613     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.601     Document Type: Article

References (22)

1. Joensuu H, Fletcher C, Dimitrijevic S, et al: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3:655-664, 2002
2. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
3. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
4. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011, 2003
5. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomized trial. Lancet 364:1127-1134, 2004
6. Rankin C, Von Mehren M, Blanke C, et al: Dose effect of imatinib in patients with metastatic GIST: Phase III sarcoma group study S0033. J Clin Oncol 22:819s, 2004 (abstr 9005, suppl 14)
7. Blay J-Y, Berthaud P, Perol D, et al: Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol 22:819s, 2004 (abstr 9006, suppl 14)
8. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
9. Fletcher JA, Corless CL, Dimitrijevic S, et al: Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22:815, 2003 (abstr 3275)
10. Debiec-Rychter M, Cools J, Dumez H, et al: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128:270-279, 2005
11. Corless CL, Fletcher AJ, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825, 2004
12. Kantarjian H, O'Brien S, Cortes J, et al: Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 10:68-75, 2004
13. O'Dwyer ME, Mauro MJ, Blasdel C, et al: Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103:451-455, 2004
14. Judson I, Donato di Paola E, Verweij J, et al: Population pharmacokinetic (PK) analysis and PK-pharmacodynamic (PD) correlations in phase I/II trial of imatinib in gastrointestinal stromal tumours (GIST) conducted by the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Proc Am Soc Clin Oncol 22:818, 2003 (abstr 3287)
15. Judson I, Ma P, Peng B, et al: Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour, a retrospective population pharmacokinetic study over time: EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55:379-386, 2005
16. Guetens G, De Boeck G, Highley M, et al: Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. J Chromatogr A 1020:27-34, 2003
17. Dumez H, Reinhart WH, Guetens G, et al: Human red blood cells: Rheological aspects, uptake, and release of cytotoxic drugs. Crit Rev Clin Lab Sci 41:159-188, 2004
18. Fletcher C, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465, 2002
19. Miettinen M, El-Rifai W, Sobin L, et al: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Hum Pathol 33:478-483, 2002
20. Emory TS, Sobin LH, Lukes L, et al: Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site. Am J Surg Pathol 23:82-87, 1999
21. Cortes J, Talpaz M, O'Brien S, et al: Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98:1105-1113, 2003
22. Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastrointestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer (in press)